INTERFERON GAMMA-1B ( DrugBank: Interferon gamma-1b, Interferon Gamma )


7 diseases
告示番号疾患名(ページ内リンク)臨床試験数
18脊髄小脳変性症(多系統萎縮症を除く。)2
65原発性免疫不全症候群1
85特発性間質性肺炎7
228閉塞性細気管支炎1
299嚢胞性線維症2
301黄斑ジストロフィー1
326大理石骨病3

18. 脊髄小脳変性症(多系統萎縮症を除く。)


臨床試験数 : 71 薬物数 : 101 - (DrugBank : 30) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 65
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01965327
(ClinicalTrials.gov)
August 201327/8/2013Interferon Gamma-1b in Friedreich Ataxia (FRDA)Open-label Pilot Study of Interferon Gamma-1b (Actimmune™) for the Treatment of Friedreich Ataxia (FRDA)Friedreich AtaxiaDrug: Interferon Gamma-1bChildren's Hospital of PhiladelphiaFriedreich's Ataxia Research Alliance;Vidara Therapeutics Research LtdCompleted5 Years17 YearsAll12Phase 2United States
2EUCTR2012-001881-14-IT
(EUCTR)
01/03/201311/01/2013A phase II clinical trial to evaluate the safety and efficacy of interferon gamma in elevating frataxin levels in Friedreich ataxia patientsA phase II clinical trial to evaluate the safety and efficacy of interferon gamma in elevating frataxin levels in Friedreich ataxia patients - GIFT/1 Friedreich's Ataxia
MedDRA version: 14.1;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: IMUKIN*SC 6F 0,5ML 100MCG
INN or Proposed INN: INTERFERON GAMMA-1B
AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Italy

65. 原発性免疫不全症候群


臨床試験数 : 482 薬物数 : 661 - (DrugBank : 119) / 標的遺伝子数 : 90 - 標的パスウェイ数 : 211
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03548818
(ClinicalTrials.gov)
May 16, 201820/3/2018Role of Interferon-gamma 1-b (IFN-?) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous DiseaseRole of Interferon-gamma 1-b (IFN-?) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous DiseaseChronic Granulomatous DiseaseDrug: Interferon Gamma-1BUniversity of Colorado, DenverNULLCompleted5 Years60 YearsAll9United States

85. 特発性間質性肺炎


臨床試験数 : 598 薬物数 : 444 - (DrugBank : 116) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 209
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-001261-17-IE
(EUCTR)
28/01/200508/12/2004An Open-Label Study of the Safety of Subcutaneous Recombinant Interferon gamma-1b in Patients with Idiopathic Pulmonary FibrosisAn Open-Label Study of the Safety of Subcutaneous Recombinant Interferon gamma-1b in Patients with Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis (IPF)Trade Name: Immukin
Product Name: Interferon gamma-1b
InterMuneNULLNot RecruitingFemale: yes
Male: yes
Phase 3Ireland
2EUCTR2004-000029-31-IE
(EUCTR)
28/01/200508/12/2004A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-Ib in patients with Idiopathic Pulmonary Fibrosis The INSPIRE Trial - International Study of Survival outcomes in IPF with Interferon gamma-1b) - INSPIREA Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-Ib in patients with Idiopathic Pulmonary Fibrosis The INSPIRE Trial - International Study of Survival outcomes in IPF with Interferon gamma-1b) - INSPIRE Idiopathic Pulmonary Fibrosis (IPF)Trade Name: Immukin
Product Name: Interferon gamma-1b
InterMuneNULLNot RecruitingFemale: yes
Male: yes
600Phase 3Ireland
3NCT00075998
(ClinicalTrials.gov)
December 200312/1/2004The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (The INSPIRE Trial)Idiopathic Pulmonary Fibrosis;Lung Disease;Pulmonary FibrosisDrug: Interferon gamma-1b (Actimmune)InterMuneNULLTerminated40 Years79 YearsBoth826Phase 3United States
4NCT00076635
(ClinicalTrials.gov)
November 200328/1/2004An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPFAn Open-Label Study of the Safety of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis;Pulmonary Fibrosis;Lung DiseaseDrug: Interferon gamma-1bInterMuneNULLTerminatedN/AN/ABoth91Phase 3United States
5NCT00052052
(ClinicalTrials.gov)
September 200221/1/2003An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis.Lung Disease;Pulmonary FibrosisDrug: interferon-gamma 1bInterMuneNULLCompleted20 Years79 YearsBoth210Phase 2United States
6NCT00052039
(ClinicalTrials.gov)
April 200221/1/2003A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving PrednisoneA Randomized, Double-Blind, Three-Arm, Phase IIIb Study Comparing the Safety and Efficacy of Interferon Gamma-1b Alone, IFN-Gamma 1b With Azathioprine, and Azathioprine Alone in Patients With Idiopathic Pulmonary Fibrosis Receiving PrednisoneLung Disease;Pulmonary FibrosisDrug: interferon-gamma 1b;Drug: azathioprineInterMuneNULLTerminated20 Years79 YearsBoth0Phase 3Italy
7NCT00047658
(ClinicalTrials.gov)
November 20019/10/2002A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Biology, and Clinical Effects of Interferon Gamma-1b Administered Subcutaneously to Patients With IPF Followed by an Open-Label ExtensionIdiopathic Pulmonary FibrosisDrug: Interferon-gamma 1bInterMuneNULLCompleted20 Years79 YearsBoth32Phase 2United States

228. 閉塞性細気管支炎


臨床試験数 : 96 薬物数 : 125 - (DrugBank : 34) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 155
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-022467-36-DE
(EUCTR)
22/06/2011A phase II study about interferon gamma 1b to therapy the steroid-refractory bronchiolitis obliterans after allogenic stem cell therapyA phase II study about interferon gamma 1b to therapy the steroid-refractory bronchiolitis obliterans after allogenic stem cell therapy steroid-refractory bronchiolitis obliterans
MedDRA version: 13.1;Level: PT;Classification code 10029888;Term: Obliterative bronchiolitis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Imukin
Product Name: Imukin
INN or Proposed INN: Interferon gamma-1b
Other descriptive name: INTERFERON GAMMA-1B
Freistaat BayernNULLNot RecruitingFemale: yes
Male: yes
Phase 2Germany

299. 嚢胞性線維症


臨床試験数 : 1,696 薬物数 : 1,658 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00043342
(ClinicalTrials.gov)
April 20027/8/2002Study of Interferon Gamma-1b by Injection for the Treatment of Patients With Cystic FibrosisA Phase I/II Study of Interferon Gamma-1b by Subcutaneous Injection for the Treatment of Patients With Cystic FibrosisCystic FibrosisDrug: interferon gamma-1bInterMuneNULLCompleted6 YearsN/ABoth51Phase 1/Phase 2United States
2NCT00043316
(ClinicalTrials.gov)
February 20017/8/2002Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic FibrosisA Phase I/II Study of Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic FibrosisCystic FibrosisDrug: interferon gamma-1bInterMuneNULLCompleted12 YearsN/ABoth66Phase 1/Phase 2United States

301. 黄斑ジストロフィー


臨床試験数 : 45 薬物数 : 48 - (DrugBank : 12) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 67
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02338973
(ClinicalTrials.gov)
January 14, 201514/1/2015Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)Pilot Phase I/II Study of the Evaluation of Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)Inherited Ophthalmic Diseases;Inherited Retinal DegenerationDrug: Interferon gamma-1bNational Eye Institute (NEI)NULLTerminated12 YearsN/AAll4Phase 1/Phase 2United States

326. 大理石骨病


臨床試験数 : 20 薬物数 : 51 - (DrugBank : 14) / 標的遺伝子数 : 16 - 標的パスウェイ数 : 80
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02666768
(ClinicalTrials.gov)
February 22, 201623/6/2015ACTIMMUNE in Intermediate OsteopetrosisOpen-label Early Phase 2 Study With a Single Arm of Interferon Gamma-1b Treatment of OsteopetrosisOsteopetrosisDrug: Interferon gamma-1bLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterUniversity of Minnesota;Horizon Pharma Ireland, Ltd., Dublin IrelandCompleted1 YearN/AAll5Phase 2United States
2NCT02584608
(ClinicalTrials.gov)
January 1, 201620/10/2015Use of ACTIMMUNE in Patients With ADO2Phase 2a Study of Interferon Gamma-1b for the Treatment of Autosomal Dominant Type 2 OsteopetrosisAutosomal Dominant Osteopetrosis Type 2Drug: ACTIMMUNEIndiana UniversityHorizon Pharma Ireland, Ltd., Dublin IrelandCompleted3 Years65 YearsAll12Phase 2United States
3NCT00043329
(ClinicalTrials.gov)
January 20027/8/2002Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant OsteopetrosisPost-Marketing Surveillance Study of Actimmune (Interferon Gamma-1b) in Patients With Severe Malignant OsteopetrosisOsteopetrosisDrug: Actimmune RegistryInterMuneNULLCompletedN/AN/ABoth6United States